See more than ever before

The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies

Detect relapse 200+ days earlier By detecting 1 part per million

See what others miss

Latest Updates

Jun 22, 2022

Foresight Diagnostics featured as part of Colorado’s growing healthcare innovation community

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

Jun 04, 2022

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

Download Poster

May 02, 2022

Jake Chabon Ph.D., Co-founder/CEO of Foresight Diagnostics joins the Berkeley Center for Law & Technology (BCLT) Expert Series podcast